Real-time PCR of BCR pathway–associated genes in persistent lymphocytes. Patient samples at baseline and 12 months of ibrutinib therapy were evaluated for gene expression of proximal signaling molecules and target genes of ERK, AKT, and NFκB. There is no consistent change in gene expression of either (A) proximal BCR genes or (B) BCR target genes.